share_log

BMO Capital Maintains Outperform on Rigel Pharmaceuticals, Lowers Price Target to $3

BMO Capital Maintains Outperform on Rigel Pharmaceuticals, Lowers Price Target to $3

BMO Capital维持瑞杰制药的跑赢大盘,将目标股价下调至3美元
Benzinga Real-time News ·  2022/11/04 10:14

BMO Capital analyst Gary Nachman maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Outperform and lowers the price target from $4 to $3.

BMO Capital分析师加里·纳赫曼维持锐杰制药(纳斯达克股票代码:RIGL)跑赢大盘,并将目标股价从4美元下调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发